Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT07347002
Enrolling by invitation Observational

Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil

NCT07347002 · tracked via the Priya Life Science Brazil tracker
Phase
Observational
Started
2026-02-02
Last updated
2026-07-17

Condition(s) studied

Chikungunya Virus Infection

Investigational drug(s) / intervention(s)

Live-attenuated CHIKV vaccine VLA1553 →

Live-attenuated CHIKV vaccine VLA1553: Non-interventional study: VLA1553 is used in the pilot vaccination strategy which is linked to this observational study.

Study summary

This is an observational, non-interventional, test-negative case-control (TNCC) study to estimate the vaccine effectiveness of VLA1553 against Chikungunya virus in a real-world setting.

Eligibility

Sex
ALL
Min age
18 Years
Max age
59 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Have a CHIKV RT-PCR result registered from a municipality where the pilot vaccination strategy is implemented and is in scope of the VLA1553-402 study; 2. Are in an eligible age-group to receive the VLA1553 vaccine; 3. Have been notified in SINAN as a suspected case for CHIK or Dengue surveillance during the study period; 4. Have a sample registered in GAL that is collected within 0-5 days following the onset of CHIKV-like symptoms and is tested for CHIKV using RT-PCR; 5. Have complete data in the Brazilian MoH databases (SINAN and GAL) on age, sex, municipality of residence, sample collection date, and date of symptom onset and the healthcare facilities where the suspected case was reported. Exclusion Criteria: 1. Have inconclusive RT-PCR result for CHIKV; 2. Have a detectable vaccine virus identified via sequencing; 3. For vaccinated and CHIV RT-PCR positive individuals, have no valid sequencing result available for RT-PCR positive samples collected within 30 days post-vaccination; 4. Have the first CHIKV-like symptom onset less than 14 days from date of vaccination.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras Belo Horizonte Minas Gerais
Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus Laranjeiras Sergipe
Fundação Faculdade Regional De Medicina De São José Do Rio Preto São Pedro São Paulo

More Valneva Austria GmbH trials in Brazil

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07347002 on ClinicalTrials.gov ↗ ← All trials in Brazil